World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
100
Citations
32550
World Ranking
8340
National Ranking
4309

Richard F. Ambinder publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Richard F. Ambinder sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 540 publications — 64th percentile

64% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Richard F. Ambinder D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Richard F. Ambinder sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 100 D-Index — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2002 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Richard F. Ambinder is affiliated with Johns Hopkins University in the United States. Their scientific work mainly focuses on the field of Medicine, with significant contributions to Oncology, Pathology and Forensic Medicine, Hematology, Immunology, and Epidemiology.

Their research topics include the following:

  • Lymphoma Diagnosis and Treatment
  • Viral-associated cancers and disorders
  • Hematopoietic Stem Cell Transplantation
  • Acute Lymphoblastic Leukemia research
  • Immune Cell Function and Interaction
  • Polyomavirus and related diseases
  • HIV Research and Treatment

Frequent co-authors collaborating with Richard F. Ambinder include:

  • Javier Bolaños-Meade
  • Nina D. Wagner-Johnston
  • Richard J. Jones
  • Ephraim J. Fuchs
  • Lode J. Swinnen

The scientist has published extensively in certain venues with notable frequency, including:

  • Blood
  • Transplantation and Cellular Therapy
  • Journal of Clinical Oncology
  • Blood Advances
  • Biology of Blood and Marrow Transplantation

Some of the recent papers by Richard F. Ambinder are:

  • National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide, 2021, Journal of Clinical Oncology
  • Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology, 2020, Journal of the National Comprehensive Cancer Network
  • Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide, 2020, Blood Advances
  • Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial, 2020, The Lancet Haematology
  • Single-cell transcriptional landscapes reveal HIV-1-driven aberrant host gene transcription as a potential therapeutic target, 2020, Science Translational Medicine

In 2002, Richard F. Ambinder was recognized as a Fellow of the American Association for the Advancement of Science (AAAS).

Best Publications

  • HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

    Leo Luznik;Paul V. O'Donnell;Paul V. O'Donnell;Heather J. Symons;Allen R. Chen

  • Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance

    William Matsui;Qiuju Wang;James P. Barber;Sarah Brennan

  • Epstein-Barr virus in AIDS-related primary central nervous system lymphoma

    E. MacMahon;P. Charache;D. Glass;R.B. Mann

  • Epstein‐Barr virus‐associated Hodgkin's disease: Epidemiologic characteristics in international data

    Sally L. Glaser;Ruby J. Lin;Susan L. Stewart;Richard F. Ambinder

  • Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010

    Lawrence D. Kaplan;Jeannette Y. Lee;Richard F. Ambinder;Joseph A. Sparano

  • Autologous Bone Marrow Transplantation in Patients with Acute Nonlymphocytic Leukemia, Using ex Vivo Marrow Treatment with 4-Hydroperoxycyclophosphamide

    Andrew M. Yeager;Herbert Kaizer;George W. Santos;Rein Saral

  • Acyclovir Halts Progression of Herpes Zoster in Immunocompromised Patients

    Balfour Hh;Bean B;Laskin Ol;Ambinder Rf

  • High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

    Leo Luznik;Javier Bolaños-Meade;Marianna Zahurak;Allen R. Chen

  • Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation.

    Richard J. Jones;Richard F. Ambinder;Steven Piantadosi;George W. Santos

  • Hodgkin lymphoma: A review and update on recent progress.

    Satish Shanbhag;Richard F. Ambinder

  • Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation.

    Atul Bedi;Carole B. Miller;Janet L. Hanson;Steven Goodman

  • Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma

    Lauri M. Burroughs;Paul V. O'Donnell;Brenda M. Sandmaier;Barry E. Storer

  • Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease

    Tzyy Choou Wu;R. B. Mann;P. Charache;S. D. Hayward

  • Chemotherapy for Human Immunodeficiency Virus–Associated Non-Hodgkin’s Lymphoma in Combination With Highly Active Antiretroviral Therapy

    Lee Ratner;Jeannette Lee;Shenghui Tang;David Redden

  • Risk-stratified outcomes of nonmyeloablative, HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

    Shannon R. McCurdy;Jennifer A. Kanakry;Margaret M. Showel;Hua Ling Tsai

  • Nonmyeloablative HLA-Haploidentical Bone Marrow Transplantation with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome

    Yvette L. Kasamon;Leo Luznik;Mary S. Leffell;Jeanne Kowalski

  • Comparison of Genetic Variability at Multiple Loci across the Genomes of the Major Subtypes of Kaposi’s Sarcoma-Associated Herpesvirus Reveals Evidence for Recombination and for Two Distinct Types of Open Reading Frame K15 Alleles at the Right-Hand End

    Lynn J. Poole;Jian Chao Zong;Dolores M. Ciufo;Donald J. Alcendor

  • Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.

    Joseph A. Sparano;Jeannette Y. Lee;Lawrence D. Kaplan;Alexandra M. Levine

  • Functional domains of Epstein-Barr virus nuclear antigen EBNA-1.

    R F Ambinder;M A Mullen;Y N Chang;G S Hayward

  • NCCN guidelines ® insights hodgkin lymphoma, version 1.2018 featured updates to the NCCN guidelines

    Richard T. Hoppe;Ranjana H. Advani;Weiyun Z. Ai;Richard F. Ambinder

Frequent Co-Authors

Richard J. Jones
Richard J. Jones Johns Hopkins University
Leo Luznik
Leo Luznik Johns Hopkins University
Ephraim J. Fuchs
Ephraim J. Fuchs Johns Hopkins University
Qian Tao
Qian Tao Chinese University of Hong Kong
Jeannette Y. Lee
Jeannette Y. Lee University of Arkansas for Medical Sciences
Michael J. Borowitz
Michael J. Borowitz Johns Hopkins University
Gary S. Hayward
Gary S. Hayward Johns Hopkins University
Marianna Zahurak
Marianna Zahurak Johns Hopkins University
Otoniel Martínez-Maza
Otoniel Martínez-Maza University of California, Los Angeles
Lee Ratner
Lee Ratner Washington University in St. Louis

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a traditional medical degree in the U.S. is a significant commitment, but there are many online degrees and career pathways worth considering in the rapidly expanding healthcare field.

For those interested in pharmacy, the 3-year online pharmd provides a flexible and accelerated route to becoming a licensed pharmacist, allowing professionals to balance their studies with existing commitments.

Those curious about the administrative side of healthcare can explore the bachelor of health information management online. This degree opens doors to roles in hospital information systems, data security, and healthcare administration.

If you’re seeking a quick entry into the healthcare workforce, there are many cheapest medical billing and coding online courses that provide foundational training for essential behind-the-scenes jobs in clinics and hospitals.

For nurses wanting to elevate their careers, the cheapest online acute care nurse practitioner programs offer advanced clinical skills and credentials, often with the flexibility of online learning.

Each of these online options offers streamlined and cost-effective opportunities to advance or begin your career in healthcare—making them excellent alternatives or complements to traditional medical studies.

Best Scientists Citing Richard F. Ambinder

Trending Scientists

Recently Published Articles